Reduced expression of H19 in bone marrow cells from chronic myeloproliferative disorders 
TO THE EDITOR
From the paternally imprinted and maternally expressed H19 gene, an untranslated RNA is generated that exerts growth regulatory functions during embryogenesis and acts as a potential tumor suppressor in some types of cancer. It is a developmentally regulated gene and, thus, abundantly expressed in several fetal tissues, and repressed in most organs after birth. 1 It has been elucidated that the untranslated RNA retains a high potency of antiproliferative effects and acts directly as a tumor suppressor.
2 So far, no H19 protein could be identified. 2 Little is known about the role of H19 in normal and neoplastic hematopoiesis. In precursor cells of patients with polycythemia vera, a reduced expression of H19 could be demonstrated. 3 To assess the level of H19 in total bone marrow cells, we quantitatively focused on its expression in reactive lesions and chronic myeloproliferative disorders (CMPD). A total of 59 formalin-fixed, paraffin-embedded (FFPE) bone marrow trephines with histopathologically proven and clinically untreated CMPD (17 polycythemia vera (PV), 11 essential thrombocythemia (ET), 11 chronic myeloid leukemia (CML), 10 idiopathic myelofibrosis (IMF) in the cellular phase, 10 IMF with demonstrable fiber increase), 12 cases with chronic myelomonocytic leukemia (CMML), and 33 control cases (bone marrow biopsies with no evidence of a neoplastic disease) were retrieved from the Bone Marrow Registry, Institute of Pathology, Medizinische Hochschule Hannover. Total RNA was extracted using an optimized protocol for the extraction of RNA from FFPE archival tissues. 5 Total RNA (1 mg), pretreated with RNase-free DNase (RQ1, Promega, USA), was transcribed to the complementary DNA (cDNA) according to the manufacture's protocol using SuperScript II Rnase À Reverse Transcriptase (Invitrogen, Karlsruhe, Germany).
As a first step to assess a potential role of H19 in normal hematopoiesis and myeloproliferative diseases, we established the quantitative RNA expression in normal bone marrow cells. In both normal bone marrow cells and those from reactive states, a relatively constant level could be found without interindividual differences. Compared to the basal expression level in controls, bone marrow cells from CMPD expressed a significantly lower H19 level. PV, ET, and CML cases showed an up to six fold reduced H19 expression (Po0.0001), while IMF in the cellular and fibrotic phases expressed three-fold less H19 (P ¼ 0.001) compared to healthy controls. CMML exhibited a 20-fold lower H19 level than control cases (Po0.0001). When compared with each other, CMPD and CMML cases did not differ significantly with regard to H19 expression, (Figure 1) .
The function and role of H19 in normal and malignant hematopoiesis largely remains unknown. A recent study demonstrated a tight regulation of H19 expression in lineage commitment. The most intriguing data, although obtained in a small-scale study, were evidence of reduced H19 expression in precursor cells of 
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Figure 1
A quantitative real-time RT-PCR assay was performed using an ABI PRISM 7700 Sequence Detection System (Applied Biosystems). Primer and probes for the quantitative analysis of H19 RNA and the housekeeping gene b-glucuronidase (b-GUS) were H19 forward primer 5 0 -TGGTTGGAGTTGTGGAGACG; H19 reverse primer 5 0 -CACTTGCCAAGGTGGCTCA; and H19 probe 5 0 -CCTTGAGTCTCAGTACGAGTGTGCGTGAGT.
b-GUS forward primer 5 0 -CTCATTTGGAATTTTGCCGATT, b-GUS reverse primer 5 0 -AGTGAAGATCCCCTTTTTA, and b-GUS probe 5 0 -TGAACAGT-CACCGACGAGAGTGCTGG. The DDC T -method for quantification of H19 RNA expression was used as previously described. 4 In CMPD and CMML cases, significantly reduced H19 RNA levels were found compared to normal bone marrow cells. Both prefibrotic and fibrotic IMF exhibited a three-fold lower level, PV, ET, and CML exhibited a six-fold lower level, and CMML cases exhibited a 20-fold lower level compared to normal bone marrow cells. To illustrate the different expression levels, the basal expression level of the control group was set to 1. Correspondence patients with PV. 3 Expression of several genes associated with positive regulation of the cell cycle and proliferation, for example, insulin-like growth factor 2 (IGF-2), seem to be regulated by H19 RNA itself as a so-called riboregulator. 6 In a previous study, the relaxation of IGF-2 imprinting and its biallelic expression in normal hematopoiesis could be demonstrated. 7 This process seems to be specific for IGF-2, because the imprinting status of H19 in this study was found to be monoallelic and therefore unaffected. The consequence of disrupted imprinting of IGF-2 in normal hematopoiesis could be an upregulation of its growth-promoting effects. 7 These effects could be exaggerated in neoplastic hematopoietic proliferations. It has been proposed that H19 participates in the repression of IGF-2, at least in part, through effects on IGF-2 transcription. 6 Reduced expression of H19 in CMPD therefore could enhance the growth-promoting effects of IGF-2. In most adult tissues, H19 and IGF-2 are reciprocally imprinted. Loss of imprinting of IGF-2 has been described in many solid tumors as well as in CML in blast crisis and acute myeloid leukemia. 8, 9 A loss of imprinting (LOI) of IGF-2 is associated with abnormal methylation and reduced expression of H19 in Wilms tumor. 10 Both LOI and abnormal methylation could lead to an altered expression of H19 and IGF-2. Our data clearly demonstrate a significantly reduced expression of H19 as the hallmark in bone marrow cells of CMPD compared to non-neoplastic states. Besides allowing a better discrimination between CMPD and reactive hematopoietic proliferation, reduced H19 expression may play an important role in the pathogenesis and growth regulatory dysfunction in these stem cell disorders.
